Skip to main content

Prandin Side Effects

Generic name: repaglinide

Medically reviewed by Last updated on Dec 23, 2023.

Note: This document contains side effect information about repaglinide. Some dosage forms listed on this page may not apply to the brand name Prandin.

Applies to repaglinide: oral tablet.

Serious side effects of Prandin

Along with its needed effects, repaglinide (the active ingredient contained in Prandin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking repaglinide:

More common

Less common

Incidence not known

Other side effects of Prandin

Some side effects of repaglinide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to repaglinide: oral tablet.


The most frequently reported adverse reactions were changes in blood glucose levels; the occurrence of these reactions was dependent on individual factors such as dietary habits, dose, exercise, and stress.[Ref]


Very common (10% or more): Hypoglycemia (up to 31%)[Ref]

In 12 to 24 week clinical trials, hypoglycemia occurred in 31% of patients receiving this drug compared to 7% of placebo-treated patients. In 1 year trials, hypoglycemia occurred in 16% of patients receiving this drug compared to 19% and 20% of glipizide and glyburide patients, respectively.[Ref]


Cardiovascular events were evaluated in trials comparing this drug to sulfonylureas. Serious cardiovascular events including ischemia with this drug were higher at 4% than for sulfonylurea drugs (3%). No excess mortality was associated with this increase. Selected cardiovascular events including hypertension, abnormal EKG, MI, arrhythmias, and palpitations were observed at 1% or less and no more frequently with this drug than with comparator drugs.

Trials of this drug in combination with NPH insulin found 6 serious events of myocardial ischemia.[Ref]

Common (1% to 10%): Chest pain, angina, serious cardiovascular events including ischemia

Frequency not reported: Hypertension, abnormal EKG, MI, arrhythmias, palpitations[Ref]


Common (1% to 10%): Allergy

Uncommon (0.1% to 1%): Allergic skin reactions such as rash, urticaria, and pruritus

Frequency not reported: Anaphylactoid reactions[Ref]

Anaphylactoid reactions were reported in less than 1% of patients. Allergic skin reactions such as rash, urticaria, and pruritus have been observed. There is no reason to suspect cross-allergenicity with sulfonylurea drugs due to the difference in chemical structure.[Ref]


Common (1% to 10%): Nausea, diarrhea, constipation, vomiting, dyspepsia, tooth disorder

Postmarketing reports: Pancreatitis[Ref]

Nervous system

Very common (10% or more): Headache (up to 11%)

Common (1% to 10%): Paresthesia[Ref]


Common (1% to 10%): Arthralgia, back pain[Ref]


Very common (10% or more): Upper respiratory infection (up to 16%)

Common (1% to 10%): Sinusitis, rhinitis, bronchitis[Ref]


Postmarketing experience has included reports of severe hepatic dysfunction including jaundice and hepatitis.[Ref]

Frequency not reported: Elevated liver enzymes

Postmarketing reports: Severe hepatic dysfunction including jaundice and hepatitis[Ref]


Thrombocytopenia or leukopenia have been reported in less than 1% of patients.[Ref]

Frequency not reported: Thrombocytopenia, leukopenia

Postmarketing reports: Hemolytic anemia[Ref]


Rare (less than 0.1%): Blurred vision

Very rare (less than 0.01%): Refraction disorder[Ref]

Refraction disorders have been known to result due to changes in blood glucose levels.[Ref]


Postmarketing reports: Alopecia, Stevens-Johnson syndrome[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


1. Product Information. Prandin (repaglinide). Novo Nordisk Pharmaceuticals Inc. 2001;PROD.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.